Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 986 participants.
Also called NCT01177813
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 986 participants
- Registry
-
NCT01177813 -
2009-016243-20
-
- Other papers using this trial's data
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Results first posted
- Countries
- United States, Belgium, Canada, China, Germany, India, Ireland, Japan, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT01177813. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2014-06-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo identical to BI10773 high dose
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- BI 10773 open label
- Intervention (Drug)
- Placebo identical to BI10773 low dose
- Intervention (Drug)
- Placebo identical to BI10773 low dose
- Intervention (Drug)
- Placebo identical to BI10773 high dose
- Intervention (Drug)
- Placebo identical to Sitagliptin 100mg
- Intervention (Drug)
- Placebo identical to Sitagliptin 100mg
- Intervention (Drug)
- BI10773
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo identical to Sitagliptin 100mg
- Intervention (Drug)
- Placebo identical to BI10773 low dose
- Intervention (Drug)
- Placebo identical to BI10773 high dose
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01177813- Content hash
a03351a0de2d9300915c6fb863ae6ff8766691e60e5ea41708dcdafccbbf84ef